BR112022013756A2 - ANTI-TRAIN2 ANTIBODIES AND METHODS OF USE THEREOF - Google Patents

ANTI-TRAIN2 ANTIBODIES AND METHODS OF USE THEREOF

Info

Publication number
BR112022013756A2
BR112022013756A2 BR112022013756A BR112022013756A BR112022013756A2 BR 112022013756 A2 BR112022013756 A2 BR 112022013756A2 BR 112022013756 A BR112022013756 A BR 112022013756A BR 112022013756 A BR112022013756 A BR 112022013756A BR 112022013756 A2 BR112022013756 A2 BR 112022013756A2
Authority
BR
Brazil
Prior art keywords
antibodies
train2
methods
trem2
antibody
Prior art date
Application number
BR112022013756A
Other languages
Portuguese (pt)
Inventor
S Dennis Mark
Gu Zhenyu
S Kariolis Mihalis
S Mahon Cathal
M Monroe Kathryn
I Park Joshua
Prorok Rachel
P Silverman Adam
Van Lengerich Bettina
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Priority claimed from PCT/US2021/013200 external-priority patent/WO2021146256A1/en
Publication of BR112022013756A2 publication Critical patent/BR112022013756A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

ANTICORPOS ANTI-TREM2 E MÉTODOS DE USO DOS MESMOS. Em um aspecto, são fornecidos anticorpos que se ligam especificamente a um receptor desencadeador humano expresso na proteína de células mieloides 2 (TREM2). Em algumas modalidades, o anticorpo diminui os níveis de TREM2 solúvel (sTREM2). Em algumas modalidades, o anticorpo intensifica a atividade de TREM2.ANTI-TRAIN2 ANTIBODIES AND METHODS OF USE THEREOF. In one aspect, antibodies are provided that specifically bind to a human trigger receptor expressed on myeloid cell protein 2 (TREM2). In some embodiments, the antibody lowers levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.

BR112022013756A 2020-01-13 2021-01-13 ANTI-TRAIN2 ANTIBODIES AND METHODS OF USE THEREOF BR112022013756A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062960663P 2020-01-13 2020-01-13
US202063070728P 2020-08-26 2020-08-26
US202063091717P 2020-10-14 2020-10-14
PCT/US2021/013200 WO2021146256A1 (en) 2020-01-13 2021-01-13 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022013756A2 true BR112022013756A2 (en) 2022-10-11

Family

ID=76760857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013756A BR112022013756A2 (en) 2020-01-13 2021-01-13 ANTI-TRAIN2 ANTIBODIES AND METHODS OF USE THEREOF

Country Status (12)

Country Link
US (2) US11124567B2 (en)
EP (1) EP4090682A1 (en)
JP (1) JP2023512450A (en)
KR (1) KR20220131246A (en)
CN (1) CN115279790A (en)
AU (1) AU2021208482A1 (en)
BR (1) BR112022013756A2 (en)
CA (1) CA3166385A1 (en)
CO (1) CO2022009744A2 (en)
IL (1) IL294655A (en)
MX (1) MX2022008582A (en)
PE (1) PE20221465A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
MA50746A (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc FUSION PROTEINS INCLUDING SUBSTITUTIVE ENZYMOTHERAPY ENZYMES
KR20220130678A (en) 2019-12-23 2022-09-27 데날리 테라퓨틱스 인크. progranulin variants
PE20231931A1 (en) 2020-10-14 2023-12-01 Denali Therapeutics Inc FUSION PROTEINS COMPRISING SULFOGLUCOSAMINE SULFOHYDROLASE ENZYMES AND METHODS THEREOF
WO2023192288A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN117624360A (en) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 Single-domain antibody for resisting TREM2 and application thereof
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
CN116041481B (en) * 2022-09-13 2024-01-19 北京湃德智健科技有限公司 Antigen polypeptide for detecting TREM2 autoantibody and application thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
EA033115B1 (en) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b
CA2922979A1 (en) 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (en) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 Prepare the method for the human monoclonal antibodies of anti-human R47H-TREM2 mutant
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR20240056629A (en) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 Modulation of stimulatory and non-stimulatory myeloid cells
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
KR20180068999A (en) 2015-10-06 2018-06-22 알렉터 엘엘씨 Anti-TREM2 antibodies and methods of use thereof
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3487886A2 (en) 2016-07-22 2019-05-29 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Trem2 cleavage modulators and uses thereof
US11634486B2 (en) 2016-12-23 2023-04-25 Bluefin Biomedicine, Inc. Anti-SEZ6L2 antibodies and antibody drug conjugates
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
CN110520440A (en) * 2017-02-17 2019-11-29 戴纳立制药公司 Anti- τ antibody and its application method
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
AU2018221731C1 (en) * 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
CN110945018A (en) 2017-07-27 2020-03-31 诺华股份有限公司 Abscisic enzyme-resistant TREM2 variants
BR112019022752A2 (en) 2017-08-03 2020-05-19 Alector Llc anti-train2 antibodies and methods of using them
LT3665192T (en) * 2017-08-10 2023-10-25 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
CN111448212A (en) 2017-09-14 2020-07-24 戴纳立制药公司 anti-TREM 2 antibodies and methods of use thereof
MA50746A (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc FUSION PROTEINS INCLUDING SUBSTITUTIVE ENZYMOTHERAPY ENZYMES
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
WO2019094608A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
CA3083660A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
BR112020013921A2 (en) 2018-01-10 2020-12-01 Denali Therapeutics Inc. transferrin receptor binding polypeptides and uses of these
MX2020012518A (en) 2018-06-18 2021-02-16 Denali Therapeutics Inc Fusion proteins comprising progranulin.
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
WO2020037150A2 (en) 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
SG11202101436SA (en) 2018-08-22 2021-03-30 Denali Therapeutics Inc Anti-her2 polypeptides and methods of use thereof
MX2021002616A (en) 2018-09-11 2021-05-12 Washington University St Louis Anti-trem-2 agonist antibodies.
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
KR102156165B1 (en) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 Monoclonal antibody with specificity for human TREM2 protein, hybridoma cell line producing the same and use thereof
MA54296A (en) 2018-11-26 2021-10-06 Denali Therapeutics Inc METHODS OF TREATING DISREGULATED LIPID METABOLISM
WO2020121195A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
US20220025065A1 (en) 2018-12-10 2022-01-27 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
WO2020123664A1 (en) 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
MA55025A (en) 2019-02-20 2021-12-29 Denali Therapeutics Inc ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
KR20220004651A (en) 2019-04-03 2022-01-11 데날리 테라퓨틱스 인크. Preparation of protein molecules comprising iduronate 2-sulfatase

Also Published As

Publication number Publication date
US20210214438A1 (en) 2021-07-15
IL294655A (en) 2022-09-01
CN115279790A (en) 2022-11-01
EP4090682A1 (en) 2022-11-23
MX2022008582A (en) 2022-08-10
CA3166385A1 (en) 2021-07-22
JP2023512450A (en) 2023-03-27
AU2021208482A1 (en) 2022-07-21
US11124567B2 (en) 2021-09-21
US20220177576A1 (en) 2022-06-09
CO2022009744A2 (en) 2022-07-19
PE20221465A1 (en) 2022-09-21
KR20220131246A (en) 2022-09-27

Similar Documents

Publication Publication Date Title
BR112022013756A2 (en) ANTI-TRAIN2 ANTIBODIES AND METHODS OF USE THEREOF
AR119683A1 (en) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO ORPHAN RECEPTOR TYROSINE KINASE-LIKE 1 (ROR1)
CO2021003724A2 (en) Sirpα-binding proteins and methods of using them
EA202192294A1 (en) ANTIBODIES TO TREM2 AND METHODS FOR THEIR APPLICATION
CL2020001974A1 (en) Anti-trem2 antibodies and methods of using them. (divisional request 201903093)
BRPI0507433C1 (en) recombinant monoclonal antibody or antigen-binding part thereof, composition, isolated nucleic acid, expression vector, and kit
MX9203401A (en) ANTAGONIST ANTIBODIES OF HUMAN INTERLEUKINA-4.
FI972390A (en) Cytokine called Lerk-7
BR0315123A (en) Erb-b1 receptor-directed pharmaceutical compositions
AR005397A1 (en) MONOCLONAL ANTIBODY AGONIST THAT IS SPECIFICALLY LINKED TO THE OB RECEIVER, A METHOD FOR IMPROVING THE PROLIFERATION OR DIFFERENTIATION IN VITRO OF A CELL RECEIVING AN OB RECEPTOR, THE USE OF AN ANTI-RECEIVER AGONIST BODY FOR THE PREPARATION OF AN METHODS TO IDENTIFY AN ANTIBODY THAT IS LINKED OR ACTIVATED TO THE RECEIVER OB THAT INCREASES THE PROLIFERATION OR DIFFERENTIATION OF A CELL
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
BR9710811A (en) Antigen-binding fragments that specifically detect nucleotide cancer cells that encode the fragments and their use for the prophylaxis and detection of cancer
ATE556717T1 (en) NEUTRALIZATION OF MONOCLONAL ANTIBODIES AGAINST CORONAVIRUS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME
BRPI0814343A2 (en) MATERIALS AND METHODS FOR SPERM SEXING SELECTION
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2010004251A (en) Anti-bst2 antibody.
BR112022011570A2 (en) ANTI-MERTK ANTIBODIES AND METHODS OF THEIR USE
ECSP22054464A (en) ANTI-TREM2 ANTIBODIES AND METHODS TO USE THEM
DK0457804T3 (en) M-CSF monoclonal antibodies that recognize a neutralizing, conformational epitope
DE69115917D1 (en) HUMANE GAMMA INTERFERON ANTAGONISTS
TR200102877T2 (en) Anti-idiotypic antibodies against antibodies that inhibit the binding of immunoglobulin to its own high affinity receptor.
AR016681A1 (en) DEPECTION OF TH2 CELLS; COMPOSITIONS; METHODS
CY1122391T1 (en) PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC
WO2018232278A3 (en) Phospho-rab antibodies, assays and methods of use thereof
AR120739A1 (en) ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF